Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.43 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL8676368 | 1.00 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| Hexane SCHEMBL4557975 | 1.00 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL9365266 | 1.00 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| Hexane SCHEMBL299439 | 1.00 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL15347870 | 0.98 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL6274726 | 0.95 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL17676315 | 0.93 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL5014419 | 0.93 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL13938058 | 0.93 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL17676311 | 0.93 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107641511-A | For the preparation method and soil remediation method of the stabilization material for administering soil | 中冶华天工程技术有限公司 | 2018-01-30 | — | — | CN | disclosed |
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2016-02-11 | — | — | US | disclosed |
| EP-2968445-A2 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | Su, Zhuang (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150025120-A1 | PYRAZOLE-ALCOHOL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-01-22 | — | — | US | disclosed |
| WO-2014145686-A2 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | SU ZHUANG (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2010046215-A2 | DIAZA-INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-04-29 | — | — | WO | disclosed |
| CN-1332961-C | Inhibitors of alpha L beta 2 mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2007-08-22 | — | — | CN | disclosed |
| CN-1651431-A | Inhibitors of alpha L beta 2 mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2005-08-10 | — | — | CN | disclosed |
| CN-1185232-C | Alpha L beta 2-mediated cell adhesion inhibitors | TANAKA SEIYAKU CO LTD (JP) | 2005-01-19 | — | — | CN | disclosed |
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | ENDORECHERCHE, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1321146-A2 | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use | Endorecherche Inc. (CA) | 2003-06-25 | — | — | EP | disclosed |
| US-6541463-B1 | 17-spirolactone derivatives of steroids | ENDORECHERCHE, INC. (CA) | 2003-04-01 | — | — | US | disclosed |
| CN-1382143-A | Alpha L beta 2-mediated cell adhesion inhibitors | TANAKA SEIYAKU CO LTD (JP) | 2002-11-27 | — | — | CN | disclosed |
| EP-1102582-A2 | INHIBITORS OF TYPE 3 3ALPHA-HYDROXYSTEROID DEHYDROGENASE | Endorecherche Inc. (CA) | 2001-05-30 | — | — | EP | disclosed |
| EP-1094798-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | Endorecherche Inc. (CA) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000007576-A2 | INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE | ENDORECHERCHE, INC. (CA) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999046279-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | ENDORECHERCHE, INC. (CA) | 1999-09-16 | — | — | WO | disclosed |
| US-5879735-A | FAT CONTINUOUS EMULSION FOR FOOD PRODUCTS CHARACTERIZED BY COMBINATION OF LOW SATURATED FATTY ACID CONTENT AND HIGH HARDNESS | LODERS-CROKLAAN B.V. (NL) | 1999-03-09 | — | — | US | disclosed |
| EP-0172041-B1 | 5,6-DIHYDRO-4H-CYCLOPENTA(B)THIOPHENE-6-CARBOXYLIC ACIDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTICAL AGENTS CONTAINING THEM | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1988-08-10 | — | — | EP | disclosed |
| EP-0172041-A1 | 5,6-Dihydro-4H-cyclopenta(b)thiophene-6-carboxylic acids, processes for their preparation and therapeutical agents containing them | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1986-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025120-A1 | PYRAZOLE-ALCOHOL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | ADH5, ADH1A, CYP3A43 | LMNA 4199/4885GPR84 2884/4885CA1 4283/4885 |
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | HSD17B11, HSD17B3, HSD17B1 | LMNA 3211/4885GPR84 3014/4885CA1 1685/4885 |
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | LMNA 3497/4885GPR84 3935/4885CA1 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.